anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of this study was to characterize the breathing patterns of individuals with obesity during routine activities such as sitting and standing, and to identify potential contributors to alterations in these patterns. Measurements performed in 20 male subjects with obesity (BMI, 31.8±1.5 kg/m2) and 20 controls (BMI, 23.5±1.4 kg/m2) included anthropometric parameters, breathing-patterns in sitting and standing positions, spirometry, maximal respiratory pressures, and diaphragm B-mode ultrasonography. Individuals with obesity exhibited lower tidal volume and increased respiratory rate to maintain a similar minute-ventilation (p<0.05). Subjects with obesity demonstrated impaired spirometry and respiratory muscle strength, with inspiratory functions being notably compromised (p<0.05). Individuals with obesity had a greater diaphragm thickness at end inspiration but lower thickening-fraction at end quiet and forced breathings and reduced diaphragmatic displacement and excursion during maximal breaths (p<0.05). BMI was negatively associated with all respiratory function markers (p<0.05). Individuals with obesity exhibit a higher respiratory rate but lower tidal volume, likely to accommodate decreased compliance and excess thoracic and abdominal fat, further hindering inspiratory function. Moreover, increased adiposity is associated with a thicker but weaker diaphragm, primarily due to the diaphragm's mechanical disadvantage rather than its intrinsic inability to generate force.
PURPOSE: To obtain the subject composition containing a specific hecogenin ester derivative and a carrier, having an inhibiting effect on cell growth and useful of improving an inflammatory syndrome and for improving and treating benign prostata hyperplasia. CONSTITUTION: This composition contains a compound of the formula (R is a 1-4C alkyl) as a pharmaceutically effective substance and a pharmaceutically compatible carrier. Hecogenin acetate (the compound of the formula wherein R is CH3 ) is commercially available as the pharmaceutically effective substance. The compound of the formula can be synthesized by a conventional method comprising esterifying hecogenin with the corresponding acid. The compound can be prepared into powder, tablets, capsules, sugar-coated tablets, pills, etc., for oral administration or into preparations for injection or infusion solutions. The preparation can be used at an extremely small dose, and is non-toxic.
The plant homeodomain zinc-finger protein, PHF6, is a transcriptional regulator, and PHF6 germline mutations cause the X-linked intellectual disability (XLID) Börjeson-Forssman-Lehmann syndrome (BFLS). The mechanisms by which PHF6 regulates transcription and how its mutations cause BFLS remain poorly characterized. Here, we show genome-wide binding of PHF6 in the developing cortex in the vicinity of genes involved in central nervous system development and neurogenesis. Characterization of BFLS mice harbouring PHF6 patient mutations reveals an increase in embryonic neural stem cell (eNSC) self-renewal and a reduction of neural progenitors. We identify a panel of Ephrin receptors (EphRs) as direct transcriptional targets of PHF6. Mechanistically, we show that PHF6 regulation of EphR is impaired in BFLS mice and in conditional Phf6 knock-out mice. Knockdown of EphR-A phenocopies the PHF6 loss-of-function defects in altering eNSCs, and its forced expression rescues defects of BFLS mice-derived eNSCs. Our data indicate that PHF6 directly promotes Ephrin receptor expression to control eNSC behaviour in the developing brain, and that this pathway is impaired in BFLS.
The present invention relates to a hypoglycemic agent using a natural plant, which is mainly composed of weight of materials listed below: 40-80 parts of Momordica charantia L.; 20-60 parts of Houttuynia cordata; 20-45 parts of Hovenia dulcis Thunb., and 10-30 parts of Poncirus trifoliata Rafin. A manufacturing method thereof makes a powder by steaming, drying and crushing the materials to make a powder, and mixing the same in a certain ratio. All the materials of the present invention are natural plants, and nontoxic medicine ingredients frequently used. The materials have effects of blue heat detoxing, collecting energy and distributing extravasated blood, distributing stasis in liver, and strengthening stomach. The hypoglycemic agent can strengthen a digestive function and a liver function, and can be good for recovering a pancreas function. A user intakes the hypoglycemic agent so as to reduce dosage of a medicine for blood sugar, to reduce blood sugar, and to reduce side effects of western drugs.
Inform patients of the availability of a Medication Guide, and instruct them to read the Medication Guide prior to taking Celontin. Instruct patients to take Celontin only as prescribed. 

Methsuximide may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a motor vehicle or other such activity requiring alertness; therefore, the patient should be cautioned accordingly. Patients taking methsuximide should be advised of the importance of adhering strictly to the prescribed dosage regimen.

Patients should be instructed to promptly contact their physician if they develop signs and/or symptoms suggesting an infection (eg, sore throat, fever).

ADVICE TO THE PHARMACIST AND PATIENT: Since methsuximide has a relatively low melting temperature (124° F), storage conditions which may promote high temperatures (closed cars, delivery vans, or storage near steam pipes) should be avoided. Do not dispense or use capsules that are not full or in which contents have melted. Effectiveness may be reduced. Protect from excessive heat (104° F).

Patients, their caregivers, and families should be counseled that AEDs, including Celontin, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.

Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see PRECAUTIONS: Pregnancy section).
This trial will measure the effects of very low doses of estradiol or estriol cream applied to the vaginal introitus for the treatment of atrophic vaginitis, a common condition affecting up to 40% of postmenopausal women. We will conduct a randomized controlled trial with three arms-estradiol, estriol and placebo. The intervention will last for 12 weeks. The outcomes we will be most interested in are the efficacy of the treatments for symptoms of atrophic vaginitis compared to placebo and whether there is any measurable systemic absorption from the locally applied estrogen creams. These outcomes will be measured, primarily, by the use of patient questionnaires and secondarily, clinical examination scores. Safety will be evaluated with serum estrogen concentrations. All measures will be collected at baseline and at the termination of the study. Hormone concentrations will be collected, additionally, at week 2. This trial will answer important questions regarding the impact of very low doses of locally applied estrogens and symptoms of atrophic vaginitis. It will provide information on effect size and validity of outcome measures. It will also give information about whether low doses of estrogen creams, locally applied to the vaginal introitus, result in systemic absorption
Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS). It is a multi-arm, multi-stage format, involving several different trial questions. FaR-RMS is intended to be a rolling programme of research with new treatment arms being introduced dependant on emerging data and innovation. This study has multiple aims. It aims to evaluate the impact of new agent regimens in both newly diagnosed and relapsed RMS; whether changing the duration of maintenance therapy affects outcome; and whether changes to dose, extent (in metastatic disease) and timing of radiotherapy improve outcome and quality of life. In addition the study will evaluate risk stratification through the use of PAX-FOXO1 fusion gene status instead of histological subtyping and explore the use of FDG PET-CT response assessment as a prognostic biomarker for outcome following induction chemotherapy.

Newly diagnosed patients should, where possible, be entered into the FaR-RMS study at the time of first diagnosis prior to receiving any chemotherapy. However, patients can enter at the point of radiotherapy or maintenance, and those with relapsed disease can enter the study even if not previously entered at initial diagnosis. Patients may be entered into more than one randomisation/registration, dependant on patient risk group and disease status.
PURPOSE:To obtain an anti-retrovirus agent comprising coloring matters such as Cibacron Brilliant Red, etc., as active ingredients. CONSTITUTION:An anti-retrovirus agent comprises a compound of formula I (R1 is group of formula II or formula III), e.g. 13 kinds of coloring matters such as Cibacron Brilliant Red, etc., as active ingredients. The agent is applicable to retrovirus such as leukemia, sarcoma virus, breast cancer Visna virus, Maedi virus, HiV, HTLV-1, etc. The compound is used for colorimetric determination of metal, dyeing, etc., and sold in the market by Aldrich chemical company Inc. compound of formula I is pharmaceutically manufactured into a dosage form such as tablet, capsule, granule, fine granule, powder, injection, suppository, etc., as it is or blended with a conventional preparation carrier and pharmaceutically manufactured and used. A dose is usually 10mg to 1g calculated as weight of the compound of formula I for adult daily and administered dividedly for several times.
PURPOSE: To investigate factors associated with intrachoroidal cavitation (ICC) and sinkhole formation in eyes with glaucomatous visual-field defects.
METHODS: This retrospective, cross-sectional study enrolled a total of 2808 eyes of 1482 patients who were diagnosed/treated for glaucoma and underwent swept-source optical coherence tomography (OCT). We first determined the prevalence of ICCs and sinkholes and their locations. Next, we selected one eye from each patient and compared the clinical characteristics of eyes with and without ICCs. Finally, in eyes with ICCs, we compared the clinical characteristics of eyes with and without sinkholes. Blood flow (BF), represented by laser speckle flowgraphy-measured tissue-area mean blur rate (MBR), was measured in the temporal optic nerve head (ONH), temporal peripapillary chorioretinal atrophy (PPA) zone, and in the ICC zone. ICC area and angle were analyzed in OCT en-face images. Mean deviation and total deviation in the central area (TD-central) were measured with Humphrey visual-field testing.
RESULTS: A total of 86 eyes (3.1%) had ICCs and 52 eyes (1.9%) had sinkholes. ICC eyes had a lower spherical equivalent and longer axial length (AL) than non-ICC eyes (P < 0.05). Patients with eyes with sinkholes were more elderly and had worse best-corrected visual acuity, worse TD-central, a larger ICC, and lower tissue-area MBR in the temporal ONH, temporal PPA zone, and ICC zone (P < 0.05).
CONCLUSION: In eyes with glaucoma, AL elongation might be linked to ICC formation. Sinkhole formation might be associated with ICC enlargement, impaired ocular BF, and impaired retinal structure and function involving the central area.
The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
NEW MATERIAL:A glycoprotein recoverable from human urine and having the following properties. Mol. wt.: approximately 70,000 measured by a gel filtration method; isoelectric point: approximately 4.7pH; amino acid sequence of the N-terminal group: formula (- means to be unmeasurable); ratio of the glucide component to the protein component: glucide content of approximately 13-20%; the glycoprotein acts on bone marrow cells to stimulate the differentiation and multiplication of granulocyte stem cells. USE:Leukopenic leukemia remedy. PREPARATION:For example, human urine is partially purified to give a soln. contg. a colony formation-stimulating factor (CSF) having increased specific activity. The soln. is mixed with polyethylene glycol, cooled with ice and centrifuged to recover the resulting precipitates. The precititates are dissolved in a 10mM phosphoric acid buffer soln. and the produced soln. is mixed with ethanol to again result precipitates. The precipitates are again dissolved in the 10mM phosphoric acid buffer soln. and then purified by a method such as ion exchange chromatography or gel filtration to provide the novel CSF.
Climate change is expected to intensify the occurrence of abiotic stress in plants, such as hypoxia and salt stresses, leading to the production of reactive oxygen species (ROS), which need to be effectively managed by various oxido-reductases encoded by the so-called ROS gene network. Here, we studied six oxido-reductases families in three Brassicaceae species, Arabidopsis thaliana as well as Nasturtium officinale and Eutrema salsugineum, which are adapted to hypoxia and salt stress, respectively. Using available and new genomic data, we performed a phylogenomic analysis and compared RNA-seq data to study genomic and transcriptomic adaptations. This comprehensive approach allowed for the gaining of insights into the impact of the adaptation to saline or hypoxia conditions on genome organization (gene gains and losses) and transcriptional regulation. Notably, the comparison of the N. officinale and E. salsugineum genomes to that of A. thaliana highlighted changes in the distribution of ohnologs and homologs, particularly affecting class III peroxidase genes (CIII Prxs). These changes were specific to each gene, to gene families subjected to duplication events and to each species, suggesting distinct evolutionary responses. The analysis of transcriptomic data has allowed for the identification of genes related to stress responses in A. thaliana, and, conversely, to adaptation in N. officinale and E. salsugineum.
PURPOSE:To obtain a dialyzing fluid preparing agent capable of readily producing a dialyzing fluid by a simple operation without causing precipitation of carbonate and almost without evolving a carbon dioxide gas, containing sodium bicarbonate, electrolytic substance and pH adjusting solution and having water content in a specific range. CONSTITUTION:A solid agent containing 20-28wt.%, especially 22-26wt.% sodium bicarbonate, 72-80wt.%, especially 74-78wt.% electrolytic substance (e.g. sodium chloride or calcium chloride) and 0.2-0.5wt.%, especially 0.3-0.4wt.% pH adjusting solution (e.g. glacial acetic acid or calcium chloride) and having water content adjusted to <=6wt.%. The solid agent may further contain 5-20wt.% glucose. A dialyzing fluid having desired concentration can be readily prepared by blending the solid agent with water. The solid agent does not require a wide storage place and is easily transportable because of being solid agent.
PURPOSE:To obtain a skin cosmetic, containing a high-molecular weight silicone and a low-boiling oil for dissolving the silicone and having good water, perspiration, oil resistance as well as makeup durability, excellent extensibility, stability and refreshing feeling of use. CONSTITUTION:A skin cosmetic containing 1-30wt.% compound expressed by the formula (R1 is methyl or partially phenyl; R2 is methyl or OH; n is 3,000-20,000) and 10-80wt.% low-boiling oil in an amount required for dissolving the above-mentioned compound. Low-boiling silicone, e.g. cyclic silicone or chain silicone, 1-30C isoparaffinic hydrocarbon, etc., are used as the low- boiling oil in an amount of preferably 1-50 times based on the high-molecular weight silicone. The above-mentioned skin cosmetic has excellent preventing effects on makeup disorder. A mixture of a surfactant with water-soluble polyhydric alcohol may be blended with an oily phase for use as an emulsified cosmetic.
Most patients suffering from acute lung injury or acute respiratory distress syndrome require mechanical ventilation. In this setting, positive end-expiratory pressure is used to improve arterial oxygenation. While the beneficial effect on clinical outcome of using low tidal volume is clearly proven, the best way to titrate PEEP is not known. Higher PEEP levels may better improve oxygenation and reduce ventilator-induced lung injury by reducing end-expiratory alveolar collapse but may also cause circulatory depression and aggravate lung injury from end-inspiratory overdistension. This trial compares the impact on outcome of two strategies for setting PEEP. In the "minimal alveolar distension" arm, PEEP is set for a total PEEP (PEEP + intrinsic PEEP) between 5 and 9 cm H20). In the "maximal alveolar recruitment" arm, PEEP is set for a plateau pressure between 28 and 30 cm H20. A tidal volume of 6 ml/kg predicted body weight is used in the two arms. The goals for arterial oxygenation and PaCO2 are the same in the two arms.
An electronic device and method for personalized recommendation for safe consumption of foods items is disclosed. The electronic device collects information associated with a user of the electronic device and determines a food item that the user intends to consume. The determination is performed based on the collected information. The electronic device queries the database to determine whether the database includes a record corresponding to the determined food item. The database is for food items that cause food allergies or food intolerances to a user. The electronic device generates a recommendation associated with the food item based on whether the database includes the record and controls the display to render the recommendation. The recommendation indicates whether the food item is safe for the user to consume in light of the food allergies or the food intolerances.
Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
Spinocerebellar ataxias (SCA) are rare inherited neurodegenerative disorders characterized by a progressive impairment of gait, balance, limb coordination, and speech. There is currently no composite scale that includes multiple aspects of the SCA experience to assess disease progression and treatment effects. Applying the method of partial least squares (PLS) regression, we developed the Spinocerebellar Ataxia Composite Scale (SCACOMS) from two SCA natural history datasets (NCT01060371, NCT02440763). PLS regression selected items based on their ability to detect clinical decline, with optimized weights based on the item's degree of progression. Following model validation, SCACOMS was leveraged to examine disease progression and treatment effects in a 48-week SCA clinical trial cohort (NCT03701399). Items from the Clinical Global Impression-Global Improvement Scale (CGI-I), the Friedreich Ataxia Rating Scale (FARS) - functional stage, and the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) were objectively selected with weightings based on their sensitivity to clinical decline. The resulting SCACOMS exhibited improved sensitivity to disease progression and greater treatment effects (compared to the original scales from which they were derived) in a 48-week clinical trial of a novel therapeutic agent. The trial analyses also provided a SCACOMS-derived estimate of the temporal delay in SCA disease progression. SCACOMS is a useful composite measure, effectively capturing disease progression and highlighting treatment effects in patients with SCA. SCACOMS will be a powerful tool in future studies given its sensitivity to clinical decline and ability to detect a meaningful clinical impact of disease-modifying treatments.
This study aimed to design a VEGFR-targeting peptide-drug conjugate with the ability to decrease tumor burden and suppress tumor angiogenesis, and to further evaluate the therapeutic effect of anti-PD-1 antibody in HCC therapy. A VEGFR-targeting peptide VEGF125 - 136 (QR) was conjugated with a lytic peptide (KLU) to form a peptide-drug conjugate QR-KLU. And the efficacy of QR-KLU in combination with anti-PD-1 antibody for HCC therapy in vivo and in vitro were evaluated. QR-KLU inhibited the proliferation and migration of mouse HCC cell line (Hepa1-6) cells under normoxic and hypoxic conditions in a dose-dependent manner. In the subcutaneous Hepa1-6 tumor model, QR-KLU combined with the anti-PD-1 antibody substantially inhibited tumor growth, promoted tumor necrosis, and prolonged the survival time of tumor-bearing mice. QR-KLU substantially inhibited hypoxia-induced expression of VEGF, promoted tumor vascular normalization, and increased cluster of differentiation 8+ (CD8+) T cell infiltration in the tumor. In addition, QR-KLU and anti-PD-1 antibody demonstrated a strong synergistic effect in promoting the activation of intratumoral CD8+ T cells, reducing the expression of immune-inhibitory factors, and increasing the expression of immune-stimulatory factors. This study proposed a novel approach for enhancing the efficacy of anti-PD-1 antibody using a VEGFR-targeting peptide-drug conjugate in HCC therapy.
For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2" / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion. Its validity and credibility have been well demonstrated.
PROBLEM TO BE SOLVED: To obtain a new steroid derivative stereoselectively synthesizable in high efficiency by an organic synthetic chemical means, having simplified structure of the side chain at 17 position, exhibiting excellent antitumor action and useful as an antitumor agent, etc. SOLUTION: The objective compound is a new steroid derivative (salt) expressed by formula I (R is a 1-13C alkyl; A is hydroxyl group or a group easily hydrolyzable to form hydroxyl group; X and Y together form oxo or a 2-3C alkylenedioxy or X and Y are each H, hydroxy, a 1-5C alkoxy or a group easily hydrolyzable to form hydroxyl group; Y is H when X is hydroxyl group, etc.; X is H when Y is hydroxyl group, etc.; Y is a 1-5C alkoxy when X is a 1-5C alkoxy). The compound is useful as an antitumor agent, etc. The compound can be synthesized in high efficiency and stereoselectivity by using a steroid expressed by formula II as a starting substance and subjecting the substance to various reactions using organic synthetic chemical means.